VIDEO: Blinatumomab 'clearly positive' for minimal residual disease-negative ALL
Click Here to Manage Email Alerts
NEW ORLEANS — In this video perspective, Richard M. Stone, MD, discusses research results on blinatumomab presented at ASH Annual Meeting and Exposition.
Research showed that consolidation therapy with blinatumomab (Blincyto, Amgen) significantly improves overall survival in patients with B-cell acute lymphoblastic leukemia who were negative for minimal residual disease after initial treatment.
"Even though there were some concerns that the bar would be set too high, it was a clearly positive trial," Stone, professor of medicine at Harvard Medical School and director of translation research in the adult leukemia program at Dana Farber Institute, said.
"My take home is that blinatumomab was erasing undetectable minimal residual disease and maybe worked best in that subset," he said.
Reference:
- Litzow MR, et al. Abstract LBA-1. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Collapse
Healio Interviews
Click Here to Manage Email Alerts